Neoadjuvant immunotherapy for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
- 1Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
- 2Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China. [email protected].
Abstract
Background and objective
Neoadjuvant and perioperative immune checkpoint inhibitor (ICI)-based strategies are increasingly being investigated in locally advanced resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma, but the overall efficacy and safety of these approaches remain uncertain. This systematic review and meta-analysis aimed to evaluate pathological response, surgical outcomes, radiological response, and treatment-related safety of ICI-containing preoperative regimens in this setting.Methods
A systematic search of PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and Scopus was conducted from 2014 to 2026. Google Scholar was also searched as a supplementary source for gray literature and citation tracking. Studies evaluating neoadjuvant or perioperative ICI-based therapy in adults with locally advanced resectable gastric or GEJ adenocarcinoma were included. Pooled estimates for pathologic complete response (pCR), major pathologic response (MPR), objective response rate (ORR), R0 resection, and safety outcomes were calculated using random-effects models.Results
Twenty studies were included. The pooled pCR rate was 22.8% (95% c.i. 18.6% to 27.6%), MPR was 49.5% (95% c.i. 41.8% to 57.1%), ORR was 60.6% (95% c.i. 42.0% to 76.6%), and R0 resection was 97.2% (95% c.i. 94.0% to 98.7%). The pooled rates of grade 3 or higher adverse events, immune-related adverse events, and postoperative surgical complications were 24.0% (95% c.i. 15.6% to 35.2%), 23.2% (95% c.i. 15.4% to 33.5%), and 26.2% (95% c.i. 19.1% to 34.7%), respectively.Conclusion
Neoadjuvant or perioperative ICI-based therapy is associated with encouraging pathological response and high R0 resection rates in locally advanced resectable gastric and GEJ adenocarcinoma. However, the available evidence is limited by substantial clinical heterogeneity and immature survival data. Larger randomized studies with longer follow-up are needed to confirm long-term oncologic benefit and better define optimal patient selection.
Related
- Efficacy and safety of apatinib-containing neoadjuvant regimens for resectable gastric and gastroesophageal junction adenocarcinoma: a systematic review and single-arm meta-analysis
- CT imaging biomarkers after neoadjuvant immunotherapy in resectable non-small cell lung cancer: from response assessment to surgical decision-making
- Umbrella review of meta-analyses: perioperative immune checkpoint inhibitor therapy in resectable gastric and gastroesophageal junction adenocarcinoma
- Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials
- Long-Term Outcomes of Anatomical and Biological Borderline Resectable Pancreatic Ductal Adenocarcinoma After Gemcitabine/S-1-Based Neoadjuvant Chemoradiotherapy
BibTeX
@article{osman2026neoadjuvant,
title = {{Neoadjuvant immunotherapy for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.}},
author = {Ifrah Mohamud Osman and Siyu Peng and Heshi Liu and Wang Zhen and Shengjie Ma and Quan Wang},
journal = {BMC surgery},
year = {2026},
month = jul,
doi = {10.1186/s12893-026-04048-y},
url = {https://europepmc.org/article/MED/42928166},
note = {CC BY},
}
RIS
TY - JOUR
TI - Neoadjuvant immunotherapy for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
AU - Ifrah Mohamud Osman
AU - Siyu Peng
AU - Heshi Liu
AU - Wang Zhen
AU - Shengjie Ma
AU - Quan Wang
PY - 2026
DA - 2026/07/29
JO - BMC surgery
DO - 10.1186/s12893-026-04048-y
UR - https://europepmc.org/article/MED/42928166
AB - Background and objective Neoadjuvant and perioperative immune checkpoint inhibitor (ICI)-based strategies are increasingly being investigated in locally advanced resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma, but the overall efficacy and safety of these approaches remain uncertain. This systematic review and meta-analysis aimed to evaluate pathological response, surgical outcomes, radiological response, and treatment-related safety of ICI-containing preoperative regimens in this setting.Methods A systematic search of PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and Scopus was conducted from 2014 to 2026. Google Scholar was also searched as a supplementary source for gray literature and citation tracking. Studies evaluating neoadjuvant or perioperative ICI-based therapy in adults with locally advanced resectable gastric or GEJ adenocarcinoma were included. Pooled estimates for pathologic complete response (pCR), major pathologic response (MPR), objective response rate (ORR), R0 resection, and safety outcomes were calculated using random-effects models.Results Twenty studies were included. The pooled pCR rate was 22.8% (95% c.i. 18.6% to 27.6%), MPR was 49.5% (95% c.i. 41.8% to 57.1%), ORR was 60.6% (95% c.i. 42.0% to 76.6%), and R0 resection was 97.2% (95% c.i. 94.0% to 98.7%). The pooled rates of grade 3 or higher adverse events, immune-related adverse events, and postoperative surgical complications were 24.0% (95% c.i. 15.6% to 35.2%), 23.2% (95% c.i. 15.4% to 33.5%), and 26.2% (95% c.i. 19.1% to 34.7%), respectively.Conclusion Neoadjuvant or perioperative ICI-based therapy is associated with encouraging pathological response and high R0 resection rates in locally advanced resectable gastric and GEJ adenocarcinoma. However, the available evidence is limited by substantial clinical heterogeneity and immature survival data. Larger randomized studies with longer follow-up are needed to confirm long-term oncologic benefit and better define optimal patient selection.
SN - 1471-2482
ER -